4.6 Article

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Sandra P. D'Angelo et al.

Summary: In patients with mMCC, first-line treatment with avelumab led to responses in 40% and durable responses in 30%, being associated with a low rate of grade 3/4 treatment-related adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)